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Introduction: New therapeutic options are necessary for patients with chronic Chagas disease, a leading cause of
heart failure in Latin American countries. Stem cell therapy focused on improving cardiac function is a promising
approach for treating heart disease. Here, we evaluated the therapeutic effects of cardiac mesenchymal stem cells
(CMSCs) in a mouse model of chronic Chagas disease.
Methods: CMSCs were isolated from green fluorescent protein (GFP) transgenic C57BL/6 mouse hearts and tested
for adipogenic, osteogenic, chondrogenic, endothelial, and cardiogenic differentiation potentials evaluated by
histochemical and immunofluorescence techniques. A lymphoproliferation assay was performed to evaluate the
immunomodulatory activity of CMSCs. To investigate the therapeutic potential of CMSCs, C57BL/6 mice chronically
infected with Trypanosoma cruzi were treated with 106 CMSCs or saline (control) by echocardiography-guided
injection into the left ventricle wall. All animals were submitted to cardiac histopathological and immunofluorescence
analysis in heart sections from chagasic mice. Analysis by quantitative real-time reverse transcription polymerase
chain reaction (qRT-PCR) was performed in the heart to evaluate the expression of cytokines involved in the
inflammatory response.
Results: CMSCs demonstrated adipogenic, osteogenic, and chondrogenic differentiation potentials. Moreover,
these cells expressed endothelial cell and cardiomyocyte features upon defined stimulation culture conditions
and displayed immunosuppressive activity in vitro. After intramyocardial injection, GFP+ CMSCs were observed in
heart sections of chagasic mice one week later; however, no observed GFP+ cells co-expressed troponin T or
connexin-43. Histopathological analysis revealed that CMSC-treated mice had a significantly decreased number
of inflammatory cells, but no reduction in fibrotic area, two months after treatment. Analysis by qRT-PCR
demonstrated that cell therapy significantly decreased tumor necrosis factor-alpha expression and increased
transforming growth factor-beta in heart samples.
Conclusions: We conclude that the CMSCs exert a protective effect in chronic chagasic cardiomyopathy primarily
through immunomodulation.* Correspondence: milena@bahia.fiocruz.br
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Heart disease remains a major cause of worldwide morbid-
ity and mortality. Despite advances in clinical and surgical
care of cardiac patients, current therapies are able to treat
symptoms, delay clinical deterioration, and increase sur-
vival but are not effective in repair induction in a diseased
heart. This is the case of chronic cardiac Chagas disease,
which is caused by the protozoan parasite Trypanosoma
cruzi and remains a leading cause of heart failure in Latin
America [1]. Therefore, a major effort is under way to de-
velop therapies aiming at regenerating the myocardium or
to stimulate endogenous repair programs.
Different cell types, such as bone marrow cells, mesen-
chymal stem cells (MSCs) from adipose tissue, and skeletal
myoblasts, have been tested in basic and applied clinical
studies [1-4]. Bone marrow cells have demonstrated limited
efficacy in many clinical trials, and this has raised the ques-
tion of its usefulness as well as increased the investigation
of other stem cell sources that may be potentially more ef-
fective in heart disease treatment. Moreover, different cell
types are likely to have therapeutic potential in various dis-
ease settings, depending on the particular cardio-pathogenic
mechanisms involved.
Adult cardiac stem cell populations have previously
been observed in both murine and human hearts, includ-
ing tissue-specific MSCs [5-14]. Owing to their multipo-
tentiality and direct action via secretion of a repertoire of
molecules that stimulate tissue regeneration and immuno-
modulation, MSCs have been used in different clinical tri-
als and experimental models that reproduce tissue damage
in order to verify their therapeutic potential [15-19].
In this study, we isolated a population of stem cells
from the heart tissue that displays cell phenotype and
immunosuppressive and differentiation potentials char-
acteristic of MSCs. The therapeutic potential of these




Male C57BL/6-Tg(CAG-EGFP)1Osb/J (The Jackson Laboratory,
Bar Harbor, ME, USA) mice (4 to 8 weeks old) were
used to obtain cardiac mesenchymal stem cells (CMSCs).
Wild-type female C57BL/6 (4 weeks old) were used for
T. cruzi infection and as non-infected controls. Animals
were maintained in the animal facility of the Center for
Biotechnology and Cell Therapy, Hospital São Rafael
(Salvador, Bahia, Brazil), with access to food and water ad
libitum. This study was approved by the local ethics commit-
tee for animal use at the Hospital São Rafael (CEUA-HSR).
Isolation and culture of stem cells
Green fluorescent protein (GFP) transgenic mice were
deeply anesthetized by using an inhaled isoflurane anestheticcircuit 2% (Abbott, Abbott Park, IL, USA) for 10 minutes
and euthanized by cervical dislocation. The hearts were
then removed to isolate CMSCs. Cardiac fragments (ap-
proximately 1 mm) were dissected and incubated with
0.1% collagenase type A (Sigma-Aldrich, St. Louis, MO,
USA) at 37°C for 30 minutes under constant stirring.
After chemical and mechanical dissociation, fragments
were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) (Gibco, Grand Island, NY, USA) supplemented
with 10% fetal bovine serum (FBS) (Gibco) and 1% Pen
Strep (Gibco) as explants in sixwell plates and incubated
at 37°C with 5% CO2. Culture medium was changed every
3 days, and on day 8, upon reaching 90% confluence, the
explants were removed from the wells and adherent cells
were trypsinized (Trypsin-EDTA 0.05%; Gibco) and trans-
ferred to tissue culture flasks containing medium supple-
mented with 10% FBS and 1% Pen Strep. The CMSC
culture was maintained in a humidified incubator at 37°C
with 5% CO2 for in vitro and in vivo studies.
Phenotypic characterization by flow cytometry
CMSCs at passage 8 were trypsinized and resuspended in
0.9% saline. The cells (5 × 105) were incubated for 5 minutes
with CD16/CD32 (BD Biosciences, San Diego, CA, USA)
with further incubation at 4°C for 30 minutes with the fol-
lowing antibodies (diluted at 1:100): Sca1-PE-Cy5.5 (Caltag
Medsystems, Buckingham, UK); CD90.2-APC, CD117-PE,
CD45-APC, CD34-Alexa Fluor 647, and CD44-PE (BD Bio-
sciences); and CD29-APC and CD105-PE (BioLegend, San
Diego, CA, USA). Isotype-identical antibodies were used as
controls. After incubation and two phosphate-buffered sa-
line (PBS) washes, the data were acquired and analyzed on
an LSRFortessa flow cytometer (BD Biosciences). At least
50,000 events were collected and analyzed.
Adipogenic, osteogenic, and chondrogenic differentiation
For adipogenic differentiation, cells were cultured in 24-
well plates with 13-mm coverslips in complete medium
(104 cells per well). After reaching 50% to 60% confluence,
the medium was removed and replaced with an adipo-
genic induction medium by using a StemPro Adipogenesis
Differentiation Kit (Gibco). To observe the fatty vacuoles
after 14 days in culture, the adipocyte differentiated cells
and their controls were fixed in 4% paraformaldehyde and
stained with Oil red solution. The images were captured
by an AX70 microscope (Olympus, Tokyo, Japan) and Ima-
gePro Plus 7.0 software (Media Cybernetics, San Diego,
CA, USA). For osteogenic differentiation, the cells were
cultured in a specific osteogenic differentiation medium
by using a StemPro Osteogenesis Differentiation Kit
(Gibco). Half of the differentiation medium was changed
every two days. Calcium-rich matrix deposition was ob-
served by staining with Alizarin red 2%. For chondrogenic
differentiation, cells were cultured for 21 days in standard
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Chondrogenesis Differentiation Kit (Gibco). Proteoglycan
synthesis evaluation was performed in preparations stained
with Alcian blue solution.
Cardiomyogenic differentiation
CMSCs were cultured in DMEM and 10% FBS in 24-well
plates with 13-mm coverslips with complete medium.
After reaching 60% confluence, cells were incubated with
10 μM 5-azacytidine (Sigma-Aldrich). A control group
was maintained in complete medium. After 24 hours of
incubation, medium was replaced and cells were cultured
in complete DMEM for an additional 4 weeks, when the
expression of molecular cardiac markers was evaluated by
immunofluorescence analysis. Cells were fixed with 4%
paraformaldehyde for 30 minutes, washed twice with PBS
for 3 minutes, and blocked with 5% bovine serum albumin
in PBS for 30 minutes. The following primary antibodies
were then applied and incubated at 4°C for 24 hours: anti-
GATA-4 and anti-connexin 43 (1:200) (Santa Cruz Bio-
technology, Inc., Santa Cruz, CA, USA). Images of differ-
entiated cells and their controls were acquired by confocal
microscopy (Olympus) and ImagePro Plus 7.0 software
(Media Cybernetics).
Endothelial cell differentiation
CMSCs were used for the endothelial cell induction proto-
col. Cells were seeded at a density of 3,000 cells per cm2 on
24-well plates in EGM-2 culture medium with supplements
(Lonza, Walkersville, MD, USA) and cultured for 10 days.
The expression of CD31, an endothelial cell marker, was
then evaluated by immunofluorescence (BD Biosciences).
On the following day, sections were incubated with Alexa
fluor 594-conjugated anti-goat IgG (Molecular Probes,
Carlsbad, CA, USA). To induce the formation of capillary-
like structures, 24-well plates were covered with 250 μL
of Matrigel (BD Biosciences) diluted 1:1 in EGM-2.
CMSCs were seeded at a density of 30,000 cells per cm2
and cultured for 24 hours. The formation of capillary-
like structures was observed over time by using an
inverted microscope (Olympus). Additionally, the per-
centage of CD31 cells before and after EGM-2 induction
was evaluated by flow cytometry with APC-conjugated
anti-CD31 (BD Biosciences) diluted 1:50 and by analysis
with the LSRFortessa flow cytometer.
Lymphoproliferation assay
C57BL/6 spleen cell suspensions were prepared in RPMI
medium (Invitrogen, Gibco-BRL, Gaithersburg, MD, USA)
supplemented with 10% fetal bovine serum (Invitrogen,
Gibco-BRL), 2 mM of L-glutamine, 0.1% RPMI 1640
vitamins solution (Sigma-Aldrich), 1 mM of sodium pyru-
vate, 10 mM of Hepes, 50 μM of 2-mercaptoethanol, and
50 μg/mL of gentamycin (Sigma-Aldrich). Splenocyteswere cultured in 96-well plates at 4 × 105 cells per well, in
a final volume of 200 μL, in triplicate, in the presence of
5 μg/mL concanavalin A (Con A) only or in the presence
of CMSCs pre-treated with 25 μg/mL mitomycin C, at dif-
ferent ratios (CMSC/splenocyte ratio of 1:1, 1:10, or
1:100). After 48 hours, plates were pulsed with 1 μCi of
methyl-3 H thymidine (PerkinElmer, Amersham, Little
Chalfont, UK) for 18 hours, and proliferation was assessed
by measurement of 3 H-thymidine uptake by using a
β-plate counter. The percentage inhibition of spleen cell
proliferation was determined in relation to controls stimu-
lated by Con A in the absence of CMSCs.
Trypanosoma cruzi infection and cell therapy
Infection of C57BL/6 mice was performed by intraperi-
toneal injection of 100 trypomastigotes of the myotropic
Colombian T. cruzi strain [20]. Groups of 10 chronic
chagasic mice (6 months post-infection) were treated
by intramyocardial injection with 106 GFP+ CMSCs pre-
pared in 50 μL of sterile 0.9% saline solution and
injected into the lateral wall of the left ventricle by using
an ultrafine needle (12.7 × 0.33 mm 29 G; BD Biosciences)
guided by an echocardiography probe RMV 707B, 30 MHz
(Vevo 707; VisualSonics, Toronto, ON, Canada). All an-
imals were anesthetized by using an inhaled isoflurane
anesthetic circuit 2% (Abbott) for 10 minutes before
and after the intramyocardial injection. Control chaga-
sic mice received the same volume of saline solution
(n = 10). One mouse from the cell therapy group died
during the intramyocardial injection. Therefore, the
cell therapy group was composed of nine mice for the
following analysis.
Cell visualization by in vivo imaging system
Transplanted CMSCs were visualized by the in vivo im-
aging system (IVIS) Kodak Image Station 4000MM PRO
equipped with a charge-coupled device camera (Eastman
Kodak Company’s Health Group, now known as Care-
stream Health, Toronto, ON, Canada). For fluorescence
imaging, the machine was configured for 550 nm excita-
tion, 600 nm emission, 3 minutes of exposure, 262 binning,
and fstop 2.5. The acquired images were analyzed with
Carestream MI Application 5.0.2.30 software (Carestream
Health). Whole body images were acquired from the ven-
tral surface of the mice. Images were acquired immediately
after intramyocardial transplantation, accompanied by an
additional follow-up analysis 1 week later, in infected mice
(6 months post-infection).
Morphometric analysis
Heart sections were analyzed by light microscopy, and
images were digitized by using a color digital video cam-
era (CoolSnap, Montreal, QC, Canada) adapted to a
BX41 microscope (Olympus). Morphometric analyses
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ware Image Pro Plus version 7.0 (Media Cybernetics).
The number of inflammatory cells was determined by
counting 10 fields (400×) per heart in hematoxylin-and-
eosin-stained sections, and the percentage of fibrosis
was determined in Masson’s trichrome-stained heart
sections (200×) as previously described [3]. All of the
analyses were blinded.
Real-time reverse transcription polymerase chain reaction
Total RNA was isolated from heart samples with TRIzol
reagent (Invitrogen, Molecular Probes, Eugene, OR, USA),
and concentration was determined by photometric meas-
urement. A High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems, Foster City, CA, USA) was used
to synthesize cDNA from 1 μg of RNA in accordance with
the recommendations of the manufacturer. Quantitative
real-time reverse transcription polymerase chain reaction
(qRT-PCR) assays were performed to detect the expres-
sion levels of tumor necrosis factor-alpha (TNF-α) (Mm
00443258 m1), interferon-gamma (IFN-γ) (Mm008017
78m1), interleukin-6 (IL-6) (Mm00446190m1), cyclooxi-
genase 2 (COX-2) (Mm01307329m1), transforming growth
factor-beta (TGF-β) (Mm00441724m1), and IL-10 (Mm00
439616m1). The qRT-PCR amplification mixtures containedFigure 1 Morphologic and multipotential characterization of cardiac
CMSCs shows a fibroblast-like morphology in culture. (B-D) CMSCs were su
differentiation was confirmed by positive staining with Oil red for adipocyt
(D). Magnification: 20×. (E) Flow cytometry analysis of CMSCs shows the pe
CD34 at passage 8.template cDNA, TaqMan Master Mix, and probes (all
from Applied Biosystems). All reactions were run in tripli-
cate on an ABI7500 Sequence Detection System (Applied
Biosystems) under standard thermal cycling conditions.
Non-template control (NTC) and non-reverse transcrip-
tion controls (No-RT) were included.
Confocal immunofluorescence analyses in heart sections
of chagasic mice
The hearts obtained from chagasic mice were cryopre-
served in Tissue-Tek (Sakura, Alphen aan den Rijn, The
Netherlands), and 10-μm sections were obtained in Leica
CM 1850 UV cryostat (Leica Microsystems, Wetzlar,
Germany). To evaluate the presence of GFP+ cells in the
heart, sections were incubated overnight with the follow-
ing primary antibodies: anti-connexin 43 and troponin T
(Santa Cruz Biotechnology, Inc.). On the following day,
sections were incubated with Alexa fluor 594-conjugated
anti-goat IgG or Alexa fluor 488-conjugated anti-rabbit
IgG (Molecular Probes, Carlsbad, CA, USA). Nuclei were
stained with 4,6-diamidino-2-phenylindole (DAPI) by
using VectaShield Hard Set mounting medium with DAPI
H-1500 (Vector Laboratories, Burlingame, CA, USA). Sec-
tions were then analyzed by using a FluoView 1000 con-
focal microscope (Olympus).mesenchymal stem cells (CMSCs). (A) Phase contrast microscopy of
bmitted to differentiation protocols into mesenchymal lineages. Cell
es (B), Alizarin red for osteocytes (C), and Alcian blue for chondrocytes
rcentages of CD29, CD90, CD45, Sca-1, CD44, CD105, CD117, and
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All continuous variables are presented as mean ± standard
error. Lymphoproliferation assay, morphometry, and qRT-
PCR were analyzed by using one-way analysis of variance
followed by Tukey’s multiple-comparison test with Prism 3.0
(GraphPad Software, San Diego, CA, USA). All differences
were considered significant at P values of less than 0.05.Figure 2 Immunofluorescence, flow cytometry, and capillary-like tube
induced for cardiac and endothelial cell differentiation. (A) Flow cytom
with EGM-2 medium. An increase in the percentage of CD31 expression w
induced CMSCs were evaluated following culture on Matrigel for 24 hours
microscopy analysis of CMSCs after 10 days of endothelial induction by EG
fluorescent protein-positive (GFP+) CMSCs (green). (D, E) Four weeks after 5
cardiac transcription factor GATA-4 (red) (D) and the gap junction protein
2-phenylindole (DAPI) (blue) for nuclei visualization. Bars represent 30 μm iResults
Morphological and phenotypical characteristics of cardiac
mesenchymal stem cells
Stem cells isolated from GFP transgenic mouse hearts
had fibroblast-like morphologic characteristics of MSCs
(Figure 1A). CMSCs were analyzed by flow cytometry to
evaluate the expression of cell surface markers used toformation analyses of cardiac mesenchymal stem cells (CMSCs)
etry analysis of CD31 expression was evaluated in cells cultured or not
as observed in EGM-2 cell cultures. (B) Tubular-like structures of
induced by EGM-2 medium (magnification: 20×). (C) Confocal
M-2 medium reveals positive staining for CD31 (red) in green
′ azacitidine induction, GFP+ CMSCs (green) began to express the
connexin 43 (red) (E). Sections were co-stained with 4,6-diamidino-
n (B) and 50 μm in (D) and (E). *** p < 0.001.
Figure 3 Concentration-dependent inhibitory effect of cardiac
mesenchymal stem cells (CMSCs) on concanavalin A-stimulated
splenocytes. Mouse splenocytes (SCs) were incubated for 2 days
with concanavalin A in the presence of different numbers of
mitomycin-treated CMSCs (CMSC/SC ratios of 1:1, 1:10, and 1:100).
Spleen cell proliferation was assessed on day 3 by pulsing with
3H-thymidine for 18 hours. Values represent the mean ± standard
error of the mean from four independent experiments performed
in triplicate. CPM = counts per minute. ** p < 0.01, *** p < 0.001.
Figure 4 Engraftment and survival of green fluorescent
protein-positive (GFP+) cardiac mesenchymal stem cells
(CMSCs) immediately and 1 week after cell transplantation in
chagasic mice. (A) The tracking of GFP+ CMSCs in chagasic mice
was performed immediately in cell transplantation by using an
in vivo image system. Arrow indicates a GFP+ fluorescent dot in the
heart of a chagasic mouse after intramyocardial injection in the left
ventricle wall. (B, C) Heart sections of CMSC-treated mice 1 week
after intramyocardial injection show the engraftment and survival of
GFP+ cells (green) in chagasic heart by confocal microscopy analysis.
GFP+ cells in the tissue did not co-express the cardiomyocyte
markers (red) troponin T (B) or connexin 43 (C). Sections were
co-stained with 4,6-diamidino-2-phenylindole (DAPI) (blue) for nuclei
visualization. Bars represent 20 μm.
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percentage of cells expressing GFP was observed in the
CMSC population. Additionally, a small percentage of
CMSCs showed expression of CD117, whereas the ma-
jority of the cells expressed MSC markers (Sca-1, CD44,
CD73, and CD90). In contrast, the percentage of cells
expressing the hematopoietic cell marker CD45 was low
in the passage used (passage 8), whereas the expression
of CD34 remained high even at passage 8 (26%).
Adipogenic, osteogenic, and chondrogenic differentiation
potential of cardiac mesenchymal stem cells
CMSC cultures lacking differentiation stimuli main-
tained the undifferentiated state (Figure 1A). Stimulation
of CMSCs with adipogenic differentiation medium for
15 days induced the accumulation of intracellular lipid,
as shown by Oil red solution staining (Figure 1B). After
14 days of culture in osteogenic differentiation medium,
cell clusters from CMSCs underwent osteoblast differen-
tiation, as revealed by staining with Alizarin red 2%,
showing the presence of calcium deposits in the cultures
(Figure 1C). Twenty-one days after culture of CMSCs in
chondrogenic differentiation medium, we observed the
initial formation of cell clusters stained with Alcian blue,
confirming the production of proteoglycans and chon-
drogenic differentiation (Figure 1D).
Endothelial cell and cardiomyogenic differentiation of
cardiac mesenchymal stem cells
We analyzed whether CMSCs cultured in EGM-2 devel-
oped an endothelial cell-like phenotype. Flow cytometry
analysis showed an increase in the expression of CD31, an
endothelial marker, after induction (Figure 2A). This was
confirmed by confocal microscopy analysis (Figure 2C).
CMSCs cultured for 10 days in EGM-2 were reseeded on
Matrigel for another 24 hours. After this period, we ob-
served the presence of capillary-like tube formation on
Matrigel, confirming the endothelial cell differentiation
potential (Figure 2B).
CMSCs were cultured for 24 hours in the presence of the
cardiomyogenic-inducing agent 5′ azacytidine. We did not
observe any spontaneous beating of CMSCs stimulated or
not with 5′ azacytidine. After 2 weeks of culture in the pres-
ence of 5′ azacytidine, we observed the expression of two
cardiomyocyte differentiation markers, Gata-4 (Figure 2D)
and connexin-43 (Figure 2E), by confocal microscopy ana-
lysis. However, we did not find an increase in troponin T
gene expression by qRT-PCR analysis during the 3 weeks of
induction with 5′ azacytidine (data not shown).
Immunomodulatory potential of cardiac mesenchymal
stem cells in vitro
To analyze the immunomodulatory potential of CMSCs, we
performed a lymphoproliferation assay by using splenocytes
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sence of CMSCs. As shown in Figure 3, the addition of
CMSCs to the cultures of activated splenocytes caused a
concentration-dependent inhibition of proliferation, demon-
strating its immunosuppressive potential in vitro.
Presence of green fluorescent protein-positive cardiac
mesenchymal stem cells in the heart and expression of
cardiac markers after intramyocardial injection in chronic
chagasic mice
Transplanted GFP+ CMSCs were observed after intramyo-
cardial injection guided by echocardiography. A fluores-
cent dot was visualized in the heart immediately after
injection by using an in vivo imaging system in three
of the nine analyzed mice, but no signal was detected in
control mice (Figure 4A). One week after intramyocardialFigure 5 Morphometric analysis of heart sections from uninfected an
(CMSCs) or saline. Representative images of sections of hearts from mice
controls are shown: heart sections of animals untreated (A) and treated (B)
with Masson’s trichrome obtained from untreated (C) and treated (D) mice
stained with H&E. (F) Percentage of fibrosis quantified in sections stained w
of the mean of 5 to 10 animals per group. *P <0.05. *** p < 0.001.injection, in vivo imaging analysis was repeated and no
signal was detected. However, GFP+ cells could be ob-
served, 1 week after injections, in heart sections of CMSC-
transplanted chagasic mice. However, none of the GFP+
cells observed co-expressed the cardiomyocyte proteins
troponin T (Figure 4B) or connexin-43 (Figure 4C).
Intramyocardial injection of cardiac mesenchymal stem
cells modulates inflammation in chronic chagasic mice
Heart fibrosis and inflammation, typical features of chronic
chagasic cardiomyopathy, were observed in T. cruzi-
infected mice. Morphometric analysis demonstrated a
significant reduction in the number of inflammatory
cells, but not in the fibrotic area, 2 months after CMSC
intramyocardial injection, when compared with saline-
treated controls (Figure 5).d chagasic mice treated with cardiac mesenchymal stem cells
euthanized 2 months after cell therapy with CMSCs and untreated
stained with hematoxylin and eosin (H&E) and heart sections stained
. (E) Number of inflammatory cells per mm2 measured in sections
ith Masson’s trichrome. Results are expressed as mean ± standard error
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anti-inflammatory factors was evaluated in heart samples.
Treatment with CMSCs produced a statistically signifi-
cant reduction in the expression of TNF-α, but TGF-β
gene expression was increased after CMSC transplant-
ation (Figure 6B and C). No significant differences were
observed in IL-6, COX-2, IFN-γ, and IL-10 gene expres-
sion between CMSC- and saline-treated groups (Figure 6A,
D, E, and F).
Discussion
Owing particularly to recent data suggesting their in-
creased cardiomyogenic potential, heart-derived stem cellsFigure 6 Gene expression of inflammatory mediators in the heart. He
mesenchymal stem cells (CMSCs) were removed 2 months after therapy and
chain reaction for the expression of interleukin-6 (IL-6) (A), tumor necrosis
non-infected), transforming growth factor-beta (TGF-β) (C) (*P <0.05 versu
(D) (*P <0.05 versus saline), cyclooxigenase 2 (COX-2) (E), and IL-10 (F) (**have been considered a promising source for use in cell
therapy for cardiac diseases [14]. Additionally, MSCs have
been isolated from the heart [7,14] by using previously
protocols for cardiac fibroblast isolation [21].
In the present study, we isolated stem cells from the
mouse heart and showed their mesenchymal features. The
analysis of CMSC surface markers showed a pattern simi-
lar to that of MSCs obtained from different sources [22].
A small percentage of CMSCs presented CD117 (c-kit) ex-
pression. The low expression frequency of CD117 on cul-
tured MSCs obtained from different organs has been
previously described [23,24]. Similar characteristics have
been described for fibroblasts obtained from differentart samples of uninfected or chagasic mice treated with saline or cardiac
analyzed by quantitative real-time reverse transcription polymerase
factor-alpha (TNF-α) (B) (*P <0.05 versus saline and ***P <0.001 versus
s saline and **P <0.01 versus non-infected), interferon-gamma (IFN-γ)
P <0.01 versus non-infected).
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these two cell populations cannot be made [25].
CMSCs obtained in our study met additional criteria
to be defined as MSCs, including differentiation potential
into adipocytes, osteocytes, chondrocytes, and endothelial
cells. These differentiation potentials are also observed in
MSCs obtained from other sources, such as the bone mar-
row [22,26], and have been observed in additional CMSC
studies [14]. However, when stimulated after previously
described cardiomyogenic protocols, CMSCs expressed
cardiac-lineage specifiers, such as GATA-4, and connexin
43, but failed to differentiate completely into beating
cardiomyocytes in vitro. Moreover, after intramyocardial
transplantation, we did not observe in vivo differentiation
into cardiomyocytes at the evaluated time points. These
findings are in contrast to previous reports describing the
generation of differentiated cardiomyocytes in vitro by
other populations of cardiac stem cells [14,27]. However,
the efficiency of differentiation of MSCs into cardiomyo-
cytes in vitro described previously is very low and has
been constantly questioned [26,27]. Thus, the protocol of
induction by using 5′ azacitidine has limitations in the in-
duction of cardiomyogenic differentiation, which was con-
firmed in the present study.
Interestingly, we demonstrated for the first time that
CMSCs have significant immunomodulatory potential both
in vitro and in vivo. When co-cultured in the presence of
splenocytes activated by Con A, CMSCs inhibited the lym-
phoproliferation in a concentration-dependent manner. Al-
though this effect was not reported for cardiac-derived
stem cells before, MSCs obtained from other sources, such
as the bone marrow, have been well characterized regard-
ing their immunomodulatory properties [28,29].
Furthermore, we demonstrated a reduction in the num-
ber inflammatory cells in the hearts of chronic chagasic
mice after intramyocardial administration of CMSCs. Ex-
perimental infection with the myotropic Colombian strain
of T. cruzi caused an intense inflammation composed
mainly of mononuclear cells (macrophages and CD4+ and
CD8+ T cells), which is one of the hallmarks of chronic
chagasic cardiomyopathy [4]. Inflammatory cell modula-
tion was accompanied by a reduction of TNF-α gene ex-
pression, but TGF-β, an anti-inflammatory cytokine, was
upregulated. Previous studies have shown similar results
with the use of MSCs obtained from adipose tissue and
from bone marrow mononuclear cells [3,30].
Treatment with CMSCs, however, did not reduce the
percentage of fibrosis. This may be explained by the fact
that CMSCs contribute to scar formation by the abundant
secretion of collagen type I deposited in the infarct area,
as described by Carlson and colleagues [7] (2011). More-
over, in the present study, it is not possible to determine
whether the beneficial effects exerted by CMSCs could
be translated into improved heart function, since thisexperimental model is not associated with impaired heart
function at the time points analyzed (unpublished data).
Conclusions
CMSCs demonstrated an immunomodulatory potential
in a Chagas disease model but did not reduce fibrosis or
contribute to cardiomyocyte formation. These results
suggest that MSCs may be beneficial in the context of
Chagas disease cardiomyopathy. We speculate that, in
combination with other cell types or factors, MSCs may
participate in tissue regeneration.
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